Pathological diagnosis of adenosquamous carcinoma is actually difficult; therefore, it is necessary to review the tumor composition when encountering cases of ALK-positive lung adenocarcinoma that respond poorly to ALK inhibitors. This evidence concerns the gene ALK and adenosquamous carcinoma.